Lactate/Cysteine Dual-Consuming Probiotic–Nanomedicine Biohybrid System for Enhanced Cancer Chemo-Immunotherapy
Nano Letters · 2024
DOI: 10.1021/acs.nanolett.4c04938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2024. Verfasst von Tian-Qiu Xie und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, P. R. China. Hauptthemen laut MEDLINE: Immunotherapy, Probiotics, Cysteine, Lactic Acid. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immunotherapy is revolutionizing oncology, but its therapeutic efficiency is still limited by the off-target toxicities and poor antitumor immune responses. By integrating the drug-loaded nanoparticles (DMnSH) with the unique metabolic traits of Veillonella parvula (Vei), a probiotic-nanomedicine conjugate Vei@DMnSH biohybrid is elaborately designed for enhanced cancer chemo-immunotherapy. Specifically, Vei@DMnSH can accumulate in hypoxic tumor sites and simultaneously consume lactate and cysteine to reverse the lactate-associated immunosuppression and impede the biosynthesis of GSH. In addition, the DMnSH nanoparticles will rapidly deplete intracellular GSH and disassemble to release DOX and Mn2+. Accompanied by the two-pronged GSH depletion, the Mn2+-mediated Fenton-like reaction can effectively generate oxidative hydroxyl radicals to induce heavy redox imbalance. Combined with the therapeutic effect of DOX, robust immunogenic cell death is provoked and subsequently activates antitumor adaptive immunity with a tumor suppression rate over 82%, synergistically enhancing the therapeutic outcomes of cancer chemo-immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, P. R. China.
- Department of Cardiology, Zhongnan Hospital, Wuhan University, Wuhan 430071, P. R. China.
ORCID-Profile: Xiao Yan, Wei-Hai Chen, Xian-Zheng Zhang
Förderung
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Zhongnan Hospital of Wuhan University
Zitieren
APA
Xie, T. Q., Yan, X., Qin, Y. T., Zhang, C., Jin, X. K., Li, Q. R., Rao, Z. Y., Zhou, H., Chen, W. H., & Zhang, X. Z. (2024). Lactate/Cysteine Dual-Consuming Probiotic–Nanomedicine Biohybrid System for Enhanced Cancer Chemo-Immunotherapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.4c04938
Vancouver
Xie TQ, Yan X, Qin YT, Zhang C, Jin XK, Li QR, et al. Lactate/Cysteine Dual-Consuming Probiotic–Nanomedicine Biohybrid System for Enhanced Cancer Chemo-Immunotherapy. Nano Letters. 2024. doi:10.1021/acs.nanolett.4c04938
BibTeX
@article{Xie2024,
author = {Xie, Tian-Qiu and Yan, Xiao and Qin, You-Teng and Zhang, Cheng and Jin, Xiao-Kang and Li, Qian-Ru and Rao, Zhi-Yong and Zhou, Hao and Chen, Wei-Hai and Zhang, Xian-Zheng},
title = {Lactate/Cysteine Dual-Consuming Probiotic–Nanomedicine Biohybrid System for Enhanced Cancer Chemo-Immunotherapy},
journal = {Nano Letters},
year = {2024},
doi = {10.1021/acs.nanolett.4c04938}
}
EUVIMED